Quercetin reduces hydroxyurea induced cytotoxicity in immortalized mouse aortic endothelial cells
- PMID: 28584711
- PMCID: PMC5455336
- DOI: 10.7717/peerj.3376
Quercetin reduces hydroxyurea induced cytotoxicity in immortalized mouse aortic endothelial cells
Abstract
Background: Chronic inflammation is a characteristic of sickle cell disease (SCD), and is invariably associated with vascular endothelial injury. Hydroxyurea (HU), a naturally cytotoxic chemotherapeutic agent, is the only FDA drug approved for SCD, and is therefore naturally cytotoxic. Quercetin (QCT) is a dietary flavonoid found ubiquitously in plants and foods that have anti-oxidative and anti-inflammatory characteristics. Our hypothesis is that dietary QCT will decrease cytotoxic effects of lipopolysaccharide (LPS) and HU induced vascular cell damage.
Methods: Lipopolysaccharide (LPS) was used to induce inflammation in immortalized mouse aortic endothelial cells (iMAECs), providing an in vitro model of inflamed endothelial cells. The cells were exposed to LPS throughout the entire experiment. Interventions included treating the LPS exposed cells with QCT, HU, or QCT + HU over 50 hours. The 50-hour period included 24 hours of varying treatments, followed by two hours of hypoxic exposure and then 24 hours under normal aerobic exposure.
Results: LDH level was significantly higher for LPS treated versus untreated cells (P = 0.0004). LPS plus 30 micromole QCT reduced the LDH (p = 0.1, trend), whereas LPS plus 100 micromoles HU, significantly increased LDH (p = 0.0004). However, LPS plus treatment with 30 micromoles QCT/100 micromoles HU, significantly reduced LDH, compared with HU alone (p = 0.0002).
Discussion: These results suggest that quercetin may be effective against vascular endothelial cell damage for iMAECs in vitro. In particular, it shows promise in preventing HU-induced cytotoxicity, surprisingly found from these results. This latter finding is important, and should be given more consideration, since HU is the only FDA-approved drug for treating sickle cell patients, and its use is rapidly increasing.
Keywords: Hydroxyurea; Quercetin; Sickle cell disease; Vascular endothelial cells.
Conflict of interest statement
The authors declare there are no competing interests.
Figures




Similar articles
-
In vitro and in vivo anti-angiogenic effects of hydroxyurea.Microvasc Res. 2014 Jul;94:106-13. doi: 10.1016/j.mvr.2014.05.009. Epub 2014 Jun 9. Microvasc Res. 2014. PMID: 24925859
-
Combined hydroxyurea and ETA receptor blockade reduces renal injury in the humanized sickle cell mouse.Acta Physiol (Oxf). 2019 Feb;225(2):e13178. doi: 10.1111/apha.13178. Epub 2018 Sep 20. Acta Physiol (Oxf). 2019. PMID: 30144292 Free PMC article.
-
Anti-inflammatory Potential of Quercetin-3-O-β-D-("2"-galloyl)-glucopyranoside and Quercetin Isolated from Diospyros kaki calyx via Suppression of MAP Signaling Molecules in LPS-induced RAW 264.7 Macrophages.J Food Sci. 2016 Oct;81(10):C2447-C2456. doi: 10.1111/1750-3841.13497. Epub 2016 Sep 20. J Food Sci. 2016. PMID: 27648736
-
Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea.Hematology. 2004 Feb;9(1):61-4. doi: 10.1080/1024533032000158869. Hematology. 2004. PMID: 14965870
-
Hydroxyurea in children: present and future.Semin Hematol. 1997 Jul;34(3 Suppl 3):22-9. Semin Hematol. 1997. PMID: 9317198 Review.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources